Last week saw the newest first-quarter earnings release from TRIAL Holdings, Inc. (TSE:141A), an important milestone in the company's journey to build a stronger business. It was a credible result overall, with revenues of JP¥355b and statutory earnings per share of JP¥28.76 both in line with analyst estimates, showing that TRIAL Holdings is executing in line with expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the current consensus from TRIAL Holdings' nine analysts is for revenues of JP¥1.46t in 2027. This would reflect a modest 4.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to jump 35% to JP¥94.58. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥1.46t and earnings per share (EPS) of JP¥91.64 in 2027. So the consensus seems to have become somewhat more optimistic on TRIAL Holdings' earnings potential following these results.
See our latest analysis for TRIAL Holdings
The consensus price target was unchanged at JP¥4,889, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on TRIAL Holdings, with the most bullish analyst valuing it at JP¥5,700 and the most bearish at JP¥3,700 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that TRIAL Holdings' revenue growth is expected to slow, with the forecast 6.1% annualised growth rate until the end of 2027 being well below the historical 27% p.a. growth over the last three years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 3.3% per year. Even after the forecast slowdown in growth, it seems obvious that TRIAL Holdings is also expected to grow faster than the wider industry.
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards TRIAL Holdings following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple TRIAL Holdings analysts - going out to 2029, and you can see them free on our platform here.
Before you take the next step you should know about the 2 warning signs for TRIAL Holdings that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.